All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
PV-ARC: ELN Clinical Signs and Symptoms for thrombotic risk in patients with PV treated with HU
Bookmark this article
|
The observational, longitudinal, retrospective, and prospective PV-ARC study (NCT06134102) aimed to investigate the impact of clinical and laboratory characteristics of PV on patients prognoses.1 A sub-analysis from the study presented during the 66th ASH Annual Meeting and Exposition by Palandri assessed the incidence of thrombosis among 739 patients with PV treated with first-line hydroxyurea (HU), and the impact of the ELN 2021 criteria for initiating cytoreductive therapy.1 |
| Key learnings |
| The IRR of thrombosis was higher in HR-THRO patients (3.0) vs LR-patients (1.1; p = 0.006) and HR-AGE patients (1.3; p = 0.002); within the HR-THRO group, IRR was highest in patients with both older age and previous thrombosis (3.5) vs thrombosis only (1.9). |
| Patients with no ELN CSSs had improved 5-year TFS vs patients with ELN CSSs across risk groups (LR, 100% vs 86.4; HR-AGE, 97.8% vs 91.4%; HR-THRO, 88.1% vs 79.5%). |
| Progressive splenomegaly (HR, 6.10; 95% CI, 1.70–21.88; p = 0.005), inadequate hematocrit control (HR, 2.20; 95% CI, 1.36–3.54; p = 0.001), and relevant CVRFs (HR, 2.56; 95% CI, 1.09–6.00; p = 0.03) were significant predictors of thrombotic risk and may be used to inform more aggressive and personalized management strategies. |
| Results suggested that ELN CSSs can identify patients with PV at increased thrombotic risk across all conventional risk categories. |
Abbreviations: ASH, American Society of Hematology; CI, confidence interval; CSSs, Clinical Signs and Symptoms; CVRF, cardiovascular risk factor; ELN, European LeukemiaNet; HR, hazard ratio; HR-AGE, high-risk, age >60 years; HR-THRO, high-risk, previous thrombosis; IRR, incidence ratio rate; LR, low-risk; PV, polycythemia vera.
- Palandri F. Revised ELN criteria in polycythemia vera identify an increased risk phenotype for thrombotic events beyond conventional risk stratification. A multicenter cooperative study. Oral abstract #242. Presented at: 66th American Society of Hematology Annual Meeting and Exposition; Dec 7–10, 2024; San Diego, US.
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox